Seres Therapeutics announced that 80% of patients treated with SER-155 in a trial for immune checkpoint inhibitor-related enterocolitis (irEC) showed improvement without immunosuppressive therapy by day 15. This condition often forces cancer patients to stop their immune therapy, so SER-155 could allow continued treatment. The company is seeking partners and funding to advance SER-155 and other programs, while also reducing facility costs by terminating leases to strengthen its financial position. Seres reported a net income of $4.6 million in Q2 2026, boosted by a $25 million milestone payment from Nestlé.
Whale wallets have accumulated about 1.54 billion XRP tokens worth $2.2 billion in 96 hours, signaling strong investor confidence as XRP trades near $1.41. This large-scale buying reduces XRP's circulating supply, potentially supporting higher prices...
BlackRock reports Bitcoin volatility has dropped from about 80 to 35-40, driven by ETFs, options, deeper liquidity, and long-term holders. Large Bitcoin holders increasingly use Bitcoin ETFs like BlackRock's IBIT to access collateralized borrowing, h...
The SEC's new five-year Innovation Exemption allows trading of tokenized U.S. stocks on public blockchains with shareholder rights equal to traditional shares. This framework could open new revenue streams for companies like Coinbase, Robinhood, and ...
Solana (SOL) is showing strong momentum in October, leading large-cap altcoins with a 9% weekly gain and breaking key resistance levels. Its relative demand is increasing compared to Ethereum and Bitcoin, supported by fresh institutional inflows into...
XRP has surpassed the $1.40 mark, signaling renewed investor interest as the XRP Ledger (XRPL) broadens its financial ecosystem beyond payments. The recent XRPL 3.4.0 upgrade introduced a lending framework supporting fixed-term, uncollateralized loan...
